This section of the website is only for UK patients that have been prescribed KEYTRUDA® (pembrolizumab).

You are about to exit this MSD website.

MSD makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information.

Inclusion of any third party link does not imply an endorsement or recommendation by MSD.

GB-PDO-01312 | Date of Preparation: November 2020

Welcome to the KEYTRUDA® (pembrolizumab) patient website

Here you can find support tools and information to help you understand your diagnosis and treatment:

Bladder cancer

View more information

Classical Hodgkin Lymphoma

View more information

Head and neck cancer

View more information

Kidney cancer

View more information

Non-small Cell Lung cancer

View more information

This website contains information about melanoma, non-small cell lung cancer (NSCLC), classical Hodgkin Lymphoma (cHL), bladder cancer, kidney cancer, head and neck cancer, your treatment for advanced melanoma, advanced NSCLC, relapsed or refractory cHL, advanced bladder cancer, advanced kidney cancer, metastatic head and neck cancer, the potential side effects and some support tools that should be available from your Healthcare Professional (HCP).

The information provided on this website is general educational information and does not take the place of your healthcare professional's medical advice. Always follow your HCP’s instructions and talk with him/her about any questions or problems you have regarding your health and treatment.

Pembrolizumab belongs to a type of cancer treatment called immunotherapy. This type of drug works with your body’s immune system, by increasing its natural ability to identify and attack cancer cells.

If you notice any symptoms while receiving your treatment, you should talk to your Healthcare Professional right away. Do not attempt to diagnose or treat side effects yourself. Be aware that side effects may occur after receiving the final dose of your treatment and can affect more than one body area. Your healthcare team will provide a copy of the Patient Safety Information Brochure and Patient Alert Card which provide information about your treatment. Please ensure you read the brochure and carry the alert card with you at all times. By reporting side effects you can help provide more information on the safety of this medicine.

Supporting documentation

KEYTRUDA® (pembrolizumab)

Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-01245 | Date of Preparation: December 2020